SANUWAVE Health Inc

SANUWAVE Health Inc(SNWV)股票分析

$2.210

-0.040 (-1.79%)收盤時

Loading chart…
最高
2.650
開盤
2.340
成交量加權均價
2.32
成交量
361.26K
市值
—
最低
2.105
成交金額
838.71K
企業價值/稅息折舊攤銷前利潤(TTM)
-141.67

Sanuwave Health, Inc. is an ultrasound and shock wave technology company. It is a provider of wound care products. It is focused on the research, development, and commercialization of its patented, non-invasive, and biological response-activating medical systems for the repair and regeneration of skin, musculoskeletal tissue, and vascular structures. It applies and researches its patented energy transfer technologies in wound healing, orthopedic/spine, and aesthetic/cosmetic. Its two primary systems are UltraMIST and PACE. The UltraMIST system provides, through a fluid mist, low-frequency, non-contact, and pain free ultrasound energy deep inside the wound bed that promotes healing. The PACE systems use acoustic pressure shockwaves generated by the Company's Pulsed Acoustic Cellular Expression technology to converge at precise selected targets to produce short duration compression burst and are used in both wound and orthopedic applications under the brand names dermaPACE and others.

AI 分析 of SANUWAVE Health Inc (SNWV)

賣出

Sanuwave Health, Inc. is not a good buy right now. The current price is $2.21, which is significantly down from its 52-week high of $36.20, reflecting a staggering 92.35% year-to-date decline. Additionally, the RSI is extremely low at 13.769, indicating oversold conditions, but this may not be a strong enough signal to counteract the underlying financial issues. The company has recently faced a 21% decrease in reimbursement rates, which could further pressure revenues. The main risk is the high debt-to-equity ratio of 688.05%, suggesting financial instability.

估值指標

SANUWAVE Health Inc(SNWV)目前預期本益比為 18.25,5 年平均預期本益比為 21.60。

預期本益比

合理
5 年均值 P/E
21.60
目前P/E
18.25
高估
37.29
低估
5.92

預期 EV/EBITDA

嚴重低估
5 年均值 EV/EBITDA
-5.23
目前EV/EBITDA
-141.67
高估
58.87
低估
-69.32

預期股價營收比

低估
5 年均值 P/S
2.63
目前P/S
0.30
高估
4.90
低估
0.35

Alphio AI 對 SNWV 的價格情境

情境價格取自當年最後一個月度預測區間。機率為固定的模型權重(25 / 50 / 25),不構成保證。

樂

樂觀

樂觀 · 25%SNWV

$40.32

情境價格

基

基準

基準 · 50%SNWV

$36.11

情境價格

悲

悲觀

悲觀 · 25%SNWV

$28.03

情境價格

事件時間軸

2026-11-05 (ET)

10:01:00

SANUWAVE Health Inc Trading Resumes

10:00:00

SANUWAVE Health Inc Trading Halted Due to Volatility

2026-07-13 (ET)

17:00:00

Sanuwave Health Q2 Revenue Expected to Reach $9.6M-$9.8M

2026-05-12 (ET)

17:10:00

Sanuwave Reports Q1 Revenue of $9.6M

17:10:00

Sanuwave Health Maintains FY26 Revenue View of $51M-$55M

資訊

SNWV 常見問題 —— 由 Alphio AI 解答

Sanuwave Health, Inc. is an ultrasound and shock wave technology company. It is a provider of wound care products. It is focused on the research, development, and commercialization of its patented, non-invasive, and biological response-activating medical systems for the repair and regeneration of skin, musculoskeletal tissue, and vascular structures. It applies and researches its patented energy transfer technologies in wound healing, orthopedic/spine, and aesthetic/cosmetic. Its two primary systems are UltraMIST and PACE. The UltraMIST system provides, through a fluid mist, low-frequency, non-contact, and pain free ultrasound energy deep inside the wound bed that promotes healing. The PACE systems use acoustic pressure shockwaves generated by the Company's Pulsed Acoustic Cellular Expression technology to converge at precise selected targets to produce short duration compression burst and are used in both wound and orthopedic applications under the brand names dermaPACE and others. It operates in the Healthcare sector.

Sanuwave Health, Inc. is not a good buy right now. The current price is $2.21, which is significantly down from its 52-week high of $36.20, reflecting a staggering 92.35% year-to-date decline. Additionally, the RSI is extremely low at 13.769, indicating oversold conditions, but this may not be a strong enough signal to counteract the underlying financial issues. The company has recently faced a 21% decrease in reimbursement rates, which could further pressure revenues. The main risk is the high debt-to-equity ratio of 688.05%, suggesting financial instability.

暫無貼文

註冊或登入後參與討論

相關文章

本頁僅供研究參考,不構成投資建議。模型可能出錯。過往表現不代表未來結果。

開始交易